Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

FDA advisors to meet May 22 on Covid vaccine strain selection amid scrutiny from Kennedy's HHS, as Novavax awaits approval ...

Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...

A leading pharmaceutical trade group urged the Department of Commerce not to place tariffs on the sector as the window for ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...